DE60024259D1 - Trennung eines humanen retrovirus - Google Patents

Trennung eines humanen retrovirus

Info

Publication number
DE60024259D1
DE60024259D1 DE60024259T DE60024259T DE60024259D1 DE 60024259 D1 DE60024259 D1 DE 60024259D1 DE 60024259 T DE60024259 T DE 60024259T DE 60024259 T DE60024259 T DE 60024259T DE 60024259 D1 DE60024259 D1 DE 60024259D1
Authority
DE
Germany
Prior art keywords
spumavirus
present
human
separation
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60024259T
Other languages
English (en)
Other versions
DE60024259T2 (de
Inventor
M Switzer
Walid Heneine
A Sandstrom
M Folks
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Government
Original Assignee
US Government
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Government filed Critical US Government
Application granted granted Critical
Publication of DE60024259D1 publication Critical patent/DE60024259D1/de
Publication of DE60024259T2 publication Critical patent/DE60024259T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/17011—Spumavirus, e.g. chimpanzee foamy virus
    • C12N2740/17021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/17011—Spumavirus, e.g. chimpanzee foamy virus
    • C12N2740/17022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/17011—Spumavirus, e.g. chimpanzee foamy virus
    • C12N2740/17041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/17043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DE60024259T 1999-06-14 2000-06-14 Trennung eines humanen retrovirus Expired - Lifetime DE60024259T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13921999P 1999-06-14 1999-06-14
US139219P 1999-06-14
PCT/US2000/016433 WO2000077177A2 (en) 1999-06-14 2000-06-14 Isolation of a human retrovirus

Publications (2)

Publication Number Publication Date
DE60024259D1 true DE60024259D1 (de) 2005-12-29
DE60024259T2 DE60024259T2 (de) 2006-07-27

Family

ID=22485625

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60024259T Expired - Lifetime DE60024259T2 (de) 1999-06-14 2000-06-14 Trennung eines humanen retrovirus

Country Status (5)

Country Link
EP (1) EP1185628B1 (de)
AT (1) ATE310807T1 (de)
AU (1) AU5489500A (de)
DE (1) DE60024259T2 (de)
WO (1) WO2000077177A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492165B1 (en) 1997-02-12 2002-12-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Retrovirus isolated from humans
WO2000024876A2 (en) 1998-10-27 2000-05-04 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Spumavirus isolated from humans
US6441114B1 (en) 1999-06-11 2002-08-27 3M Innovative Properties Company Adhesives for use on fluorine-containing or polycarbonate surfaces
US6800475B1 (en) 1999-06-14 2004-10-05 The United States Of America As Represented By The Department Of Health And Human Services Isolation of a human retrovirus
WO2019209557A1 (en) 2018-04-27 2019-10-31 Mayo Foundation For Medical Education And Research Foamy viruses and methods of use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882912A (en) * 1997-02-12 1999-03-16 Center For Disease Control And Prevention Retrovirus isolated from humans

Also Published As

Publication number Publication date
ATE310807T1 (de) 2005-12-15
DE60024259T2 (de) 2006-07-27
AU5489500A (en) 2001-01-02
EP1185628B1 (de) 2005-11-23
WO2000077177A2 (en) 2000-12-21
EP1185628A2 (de) 2002-03-13
WO2000077177A3 (en) 2001-08-23

Similar Documents

Publication Publication Date Title
Masopust et al. Dynamic T cell migration program provides resident memory within intestinal epithelium
Beljanski et al. Enhanced influenza virus-like particle vaccination with a structurally optimized RIG-I agonist as adjuvant
ATE314095T1 (de) Virusähnliche partikel zur induktion von autoantikörpern
RU2432358C2 (ru) Способ уничтожения злокачественной клетки
FR11C0027I2 (fr) Virus de l'influenza recombinants pour vaccins et traitement genetique
EA200400376A1 (ru) Пептиды, полученные из казеина, и их использование в терапии
MX2020000221A (es) Secuencias de aminoacidos y de acidos nucleicos de adenovirus de grandes simios no humanos, vectores que contienen las mismas y usos de las mismas.
Chandler et al. Immunomodulatory effects of hydroxychloroquine and chloroquine in viral infections and their potential application in retinal gene therapy
SG156652A1 (en) Yeast-based therapeutic for chronic hepatitis c infection
KR102195196B1 (ko) 종양원성 바이러스성 폴리펩티드 양성 종양 치료용 폴리뉴클레오티드
CN107073089A (zh) 用于癌症疫苗的包被的溶瘤腺病毒
CN103386128B (zh) 一种含联合佐剂的结核亚单位疫苗
MX2009008118A (es) Polipeptido e2 del virus del papiloma usado para vacunacion.
EA199800746A1 (ru) Способ генерации противовирусного иммунного ответа у человека или животного
Janelle et al. Mutations in the glycoprotein of vesicular stomatitis virus affect cytopathogenicity: potential for oncolytic virotherapy
Kennedy et al. A vaccine based on recombinant modified Vaccinia Ankara containing the nucleoprotein from Lassa virus protects against disease progression in a guinea pig model
Cruz et al. Monocyte‐derived dendritic cells enhance protection against secondary influenza challenge by controlling the switch in CD8+ T‐cell immunodominance
GB2429711A (en) Heart and skeletal muscle inflammation (HSMI) virus
ATE310807T1 (de) Trennung eines humanen retrovirus
Takeda et al. Enhanced susceptibility of B lymphoma cells to measles virus by E pstein–B arr virus type III latency that upregulates CD 150/signaling lymphocytic activation molecule
Kos et al. Induction of primary anti‐viral cytotoxic T cells by in vitro stimulation with short synthetic peptide and interleukin‐7
DE69633919D1 (de) Mehrzweckvakzine gegen umhüllte viren
CN106421774B (zh) PreS1用于制备乙肝疫苗以及治疗慢性乙型肝炎的用途
WO2002039116A3 (en) Retrovirus isolated from humans
Russo et al. Intranasal liposomal formulation of spike protein adjuvanted with CpG protects and boosts heterologous immunity of hACE2 transgenic mice to SARS-CoV-2 infection

Legal Events

Date Code Title Description
8364 No opposition during term of opposition